Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 5 results
Author Title Type [ Year(Asc)]
Filters: Author is Lasch, Karen  [Clear All Filters]
2020
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
2019
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..  2019.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
2018
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..  2018.  Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.